CRT may become a candidate drug for the treatment of DKD by reversing the imbalance in the immune-inflammatory system mediated by the PI3K/AKT/NF-κB/IL-1β/TNF-α signaling pathway (Ma et al., 2022). The gene discussed is NFKB1; the disease is diabetic kidney disease.